Targeting attenuated interferon-α to myeloma cells with a CD38 antibody induces potent tumor regression with reduced off-target activity

PLoS ONE

Volumn 11, Issue 9, 2016, Pages

  Pogue, Sarah L ^a   Taura, Tetsuya ^a   Bi, Mingying ^a   Yun, Yong ^a   Sho, Angela ^a   Mikesell, Glen ^a   Behrens, Collette ^b   Sokolovsky, Maya ^c   Hallak, Hussein ^c   Rosenstock, Moti ^c   Sanchez, Eric ^d   Chen, Haiming ^d   Berenson, James ^d   Doyle, Anthony ^b   Nock, Steffen ^a   Wilson, David S ^a  

^a Teva Pharmaceuticals   (United States)

^b Teva Pharmaceuticals   (Australia)

^c TEVA PHARMACEUTICALS   (Israel)

^d INSTITUTE FOR MYELOMA AND BONE CANCER RESEARCH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ALPHA INTERFERON; BORTEZOMIB; CD38 ANTIGEN; DARATUMUMAB; DEXAMETHASONE; IMMUNOCYTOKINE; LENALIDOMIDE; ALPHA BETA INTERFERON RECEPTOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANIMAL TISSUE; ANTINEOPLASTIC ACTIVITY; ARTICLE; CONTROLLED STUDY; DISEASE MODEL; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG POTENTIATION; DRUG SAFETY; DRUG SPECIFICITY; DRUG TARGETING; GENE MUTATION; HUMAN; HUMAN CELL; IN VITRO STUDY; MACACA FASCICULARIS; MOUSE; MULTIPLE MYELOMA; MULTIPLE MYELOMA CELL LINE; NONHUMAN; TREATMENT OUTCOME; TUMOR REGRESSION; TUMOR XENOGRAFT; ANIMAL; CELL CULTURE; CELL SURVIVAL; DRUG EFFECTS; DRUG SCREENING; FLOW CYTOMETRY; GENETICS; METABOLISM; MUTATION;

ANIMALS; ANTIGENS, CD38; CELL SURVIVAL; CELLS, CULTURED; FLOW CYTOMETRY; HUMANS; INTERFERON-ALPHA; MACACA FASCICULARIS; MULTIPLE MYELOMA; MUTATION; RECEPTOR, INTERFERON ALPHA-BETA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84990946601     PISSN: None     EISSN: 19326203     Source Type: Journal    
DOI: 10.1371/journal.pone.0162472     Document Type: Article

References (48)

1. InstituteNC. SEER stat fact sheets:myeloma [cited 2015 September 10]. Available from: http://seer. cancer.gov/statfacts/html/mulmy.html.
2. Raab MS, Podar K, Breitkreutz I, Richardson PG, Anderson KC. Multiplemyeloma. Lancet. 2009; 374 (9686):324-39. doi: 10.1016/S0140-6736(09)60221-X PMID: 19541364.
3. El-Amm J, Tabbara IA. Emerging Therapies in Multiple Myeloma. Am J Clin Oncol. 2013. doi: 10.1097/COC.0b013e3182a4676b PMID: 23934133.
4. Siegel R, Ma J, Zou Z, Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014; 64(1):9-29. doi: 10. 3322/caac.21208 PMID: 24399786.
5. Belardelli F, Ferrantini M, Proietti E, Kirkwood JM. Interferon-Alpha in tumor immunity and immunotherapy. Cytokine Growth Factor Rev. 2002; 13(2):119-34. PMID: 11900988.
6. Rizza P, Moretti F, Belardelli F. Recent advances on the immunomodulatory effects of IFN-Alpha: implications for cancer immunotherapy and autoimmunity. Autoimmunity. 2010; 43(3):204-9. doi: 10.3109/08916930903510880 PMID: 20187707.
7. Mellstedt H, Ahre A, Bjorkholm M, Holm G, Johansson B, Strander H. Interferon therapy inmyelomatosis. Lancet. 1979; 1(8110):245-7. PMID: 84901.
8. Fritz E, Ludwig H. Interferon-Alpha treatment inmultiplemyeloma: meta-Analysis of 30 randomised trials among 3948 patients. Ann Oncol. 2000; 11(11):1427-36. PMID: 11142483.
9. Al-Zahrani H, Gupta V, MindenMD, Messner HA, Lipton JH. Vascular events associated with alpha interferon therapy. Leuk Lymphoma. 2003; 44(3):471-5. doi: 10.1080/1042819021000055066 PMID: 12688317.
10. Kirkwood J. Cancer immunotherapy: the interferon-Alpha experience. Semin Oncol. 2002; 29(3 Suppl 7):18-26. PMID: 12068384.
11. Ludwig H, Cohen AM, Polliack A, Huber H, NachbaurD, Senn HJ, et al. Interferon-Alpha for induction and maintenance inmultiplemyeloma: results of two multicenter randomized trials and summary of other studies. Ann Oncol. 1995; 6(5):467-76. PMID: 7669712.
12. O'BrienS, Kantarjian H, Talpaz M. Practical guidelines for the management of chronicmyelogenous leukemia with interferon alpha. Leuk Lymphoma. 1996; 23(3-4):247-52. doi: 10.3109/10428199609054827 PMID: 9031105.
13. Schaar CG, Kluin-Nelemans HC, Te MarveldeC, le Cessie S, BreedWP, Fibbe WE, et al. Interferonalpha as maintenance therapy in patients withmultiplemyeloma. Ann Oncol. 2005; 16(4):634-9. doi: 10.1093/annonc/mdi125 PMID: 15741226.
14. List T, NeriD. Immunocytokines: a review of molecules in clinical development for cancer therapy. Clin Pharmacol. 2013; 5:29-45. doi: 10.2147/CPAA.S49231 PMID: 23990735; PubMed Central PMCID: PMC3753206.
15. Pasche N, NeriD. Immunocytokines: a novel class of potent armedantibodies. Drug Discov Today. 2012; 17(11-12):583-90. doi: 10.1016/j.drudis.2012.01.007 PMID: 22289353.
16. Huang TH, Chintalacharuvu KR, Morrison SL. Targeting IFN-Alpha to B cell lymphoma by a tumor-specific antibody elicits potent antitumor activities. J Immunol. 2007; 179(10):6881-8. PMID: 17982079.
17. Ozzello L, De Rosa CM, BlankEW, Cantell K, Ceriani RL, Habif DV Sr. The use of natural interferon alpha conjugated to a monoclonal antibody anti mammary epithelial mucin (Mc5) for the treatment of human breast cancer xenografts. Breast Cancer Res Treat. 1993; 25(3):265-76. PMID: 8369527.
18. Rossi EA, Rossi DL, Cardillo TM, Stein R, Goldenberg DM, Chang CH. Preclinical studies on targeted delivery ofmultiple IFNalpha2b to HLA-DR in diverse hematologic cancers. Blood. 2011; 118(7):1877-84. doi: 10.1182/blood-2011-03-343145 PMID: 21680794; PubMed Central PMCID: PMC3158718.
19. Xuan C, Steward KK, TimmermanJM, Morrison SL. Targeted delivery of interferon-Alpha via fusion to anti-CD20 results in potent antitumor activity against B-cell lymphoma. Blood. 2010; 115(14):2864-71. doi: 10.1182/blood-2009-10-250555 PMID: 20139095; PubMed Central PMCID: PMC2854431.
20. Frey K, Zivanovic A, Schwager K, NeriD. Antibody-based targeting of interferon-Alpha to the tumor neovasculature: a critical evaluation. Integr Biol (Camb). 2011; 3(4):468-78. doi: 10.1039/c0ib00099j PMID: 21225052.
21. Garcin G, Paul F, Staufenbiel M, Bordat Y, Van der Heyden J, Wilmes S, et al. High efficiency cell-specific targeting of cytokine activity. Nat Commun. 2014; 5:3016. doi: 10.1038/ncomms4016 PMID: 24398568.
22. Thakur ML, Li J, Donegan M, Pallela VR, Kolan H, Duggaraju R, et al. Improved antibody targeting with interferon-Alpha-2b conjugate. J Immunother. 1997; 20(3):194-201. PMID: 9181457.
23. Yang X, Zhang X, Fu ML,WeichselbaumRR, Gajewski TF, Guo Y, et al. Targeting the tumor microenvironment with interferon-beta bridges innate and adaptive immune responses. Cancer Cell. 2014; 25 (1):37-48. doi: 10.1016/j.ccr.2013.12.004 PMID: 24434209; PubMed Central PMCID: PMC3927846.
24. Yoo EM, Trinh KR, Tran D, Vasuthasawat A, Zhang J, Hoang B, et al. Anti-CD138-targeted interferon is a potent therapeutic againstmultiplemyeloma. J Interferon Cytokine Res. 2015; 35(4):281-91. doi: 10. 1089/jir.2014.0125 PMID: 25353626; PubMed Central PMCID: PMC4390003.
25. Kim D, Park CY, MedeirosBC,Weissman IL. CD19-CD45 low/-CD38 high/CD138+ plasma cells enrich for human tumorigenicmyeloma cells. Leukemia. 2012; 26(12):2530-7. doi: 10.1038/leu.2012. 140 PMID: 22733078.
26. Lin P, Owens R, Tricot G, Wilson CS. Flow cytometricimmunophenotypic analysis of 306 cases ofmultiplemyeloma. Am J Clin Pathol. 2004; 121(4):482-8. doi: 10.1309/74R4-TB90-BUWH-27JX PMID: 15080299.
27. Santonocito AM, Consoli U, Bagnato S, Milone G, Palumbo GA, Di Raimondo F, et al. Flow cytometric detection of aneuploid CD38(++) plasmacells and CD19(+) B-lymphocytes in bone marrow, peripheral blood and PBSC harvest in multiplemyeloma patients. Leuk Res. 2004; 28(5):469-77. doi: 10.1016/j. leukres.2003.09.015 PMID: 15068900.
28. deWeers M, Tai YT, van der Veer MS, Bakker JM, Vink T, Jacobs DC, et al. Daratumumab, a novel therapeutic human CD38 monoclonal antibody, induces killing ofmultiplemyeloma and other hematological tumors. J Immunol. 2011; 186(3):1840-8. doi: 10.4049/jimmunol.1003032 PMID: 21187443.
29. Schlesinger JJ, Brandriss MW, Monath TP. Monoclonal antibodies distinguish between wild and vaccine strains of yellow fever virus by neutralization, hemagglutination inhibition, and immune precipitation of the virus envelope protein. Virology. 1983; 125(1):8-17. PMID: 6187129.
30. Piehler J, Roisman LC, Schreiber G. New structural and functional aspects of the type I interferonreceptor interaction revealed by comprehensive mutational analysis of the binding interface. J Biol Chem. 2000; 275(51):40425-33. doi: 10.1074/jbc.M006854200 PMID: 10984492.
31. Durocher Y, Perret S, Kamen A. High-level and high-throughput recombinant protein production by transient transfection of suspension-growing human 293-EBNA1 cells. Nucleic Acids Res. 2002; 30(2): E9. PMID: 11788735; PubMed Central PMCID: PMC99848.
32. CommitteeNRCU. Guide for the care and use of laboratory animals, 8th edition. Washingon (DC): National Academies Press (US); 2011.
33. OlfertED, Cross BM, McWilliam AA. Guide to the care and use of experimental animals, 2nd edition: Canadian Council on Animal Care; 1993.
34. DrydenMW, Payne PA, Ridley R, Smith V. Comparison of common fecal flotation techniques for the recovery of parasite eggs and oocysts. Vet Ther. 2005; 6(1):15-28. PMID: 15906267.
35. Campbell RA, Manyak SJ, Yang HH, Sjak-Shie NN, Chen H, Gui D, et al. LAGlambda-1: a clinically relevant drug resistant humanmultiplemyeloma tumormurine model that enables rapid evaluation of treatments for multiplemyeloma. Int J Oncol. 2006; 28(6):1409-17. PMID: 16685443.
36. Campbell RA, Berenson JR. Animal models ofmultiplemyeloma and their utility in drug discovery. Curr Protoc Pharmacol. 2008;Chapter 14:Unit 14 9. doi: 10.1002/0471141755.ph1409s40 PMID: 22294221.
37. Friedman RM. Clinical uses of interferons. Br J Clin Pharmacol. 2008; 65(2):158-62. doi: 10.1111/j. 1365-2125.2007.03055.x PMID: 18070219; PubMed Central PMCID: PMC2253698.
38. Trown PW, Wills RJ, Kamm JJ. The preclinical development of Roferon-A. Cancer. 1986; 57(8 Suppl):1648-56. PMID: 3081245.
39. Stewart WEI. "Species specificity" of interferons. The Interferon System. Wein, New York: Springer-Verlag; 1981. p. 135-45.
40. Chillemi A, Zaccarello G, Quarona V, Lazzaretti M, Martella E, Giuliani N, et al. CD38 and bone marrow microenvironment. Front Biosci (Landmark Ed). 2014; 19:152-62. PMID: 24389178.
41. Osborn BL, Olsen HS, Nardelli B, Murray JH, Zhou JX, Garcia A, et al. Pharmacokinetic and pharmacodynamic studies of a human serumalbumin-interferon-Alpha fusion protein in cynomolgus monkeys. J Pharmacol Exp Ther. 2002; 303(2):540-8. doi: 10.1124/jpet.102.037002 PMID: 12388634.
42. Jeon S, Juhn JH, Han S, Lee J, Hong T, Paek J, et al. Saturable human neopterin response to interferon-Alpha assessed by a pharmacokinetic-pharmacodynamic model. J Transl Med. 2013; 11:240. doi: 10.1186/1479-5876-11-240 PMID: 24088361; PubMed Central PMCID: PMC3853247.
43. Padovan E, Spagnoli GC, Ferrantini M, Heberer M. IFN-Alpha2a induces IP-10/CXCL10 and MIG/CXCL9 production in monocyte-derived dendritic cells and enhances their capacity to attract and stimulate CD8+ effector T cells. J Leukoc Biol. 2002; 71(4):669-76. PMID: 11927654.
44. Boccadoro M, Morgan G, Cavenagh J. Preclinical evaluation of the proteasome inhibitor bortezomib in cancer therapy. Cancer Cell Int. 2005; 5(1):18. doi: 10.1186/1475-2867-5-18 PMID: 15929791; PubMed Central PMCID:PMCPMC1164423.
45. Rozewski DM, Herman SE, Towns WH2nd, Mahoney E, Stefanovski MR, Shin JD, et al. Pharmacokinetics and tissue disposition of lenalidomide in mice. AAPS J. 2012; 14(4):872-82. doi: 10.1208/s12248-012-9401-2 PMID: 22956478; PubMed Central PMCID:PMCPMC3475844.
46. McLaughlin F, Mackintosh J, Hayes BP, McLaren A, Uings IJ, Salmon P, et al. Glucocorticoid-induced osteopenia in the mouse as assessed by histomorphometry, microcomputed tomography, and biochemical markers. Bone. 2002; 30(6):924-30. PMID: 12052464.
47. Rossi EA, Goldenberg DM, Cardillo TM, Stein R, Chang CH. CD20-targeted tetrameric interferonalpha, a novel and potent immunocytokine for the therapy of B-cell lymphomas. Blood. 2009; 114 (18):3864-71. doi: 10.1182/blood-2009-06-228890 PMID: 19710501; PubMed Central PMCID: PMC2773491.
48. Sondergeld P, van de Dong NWCJ, Richardson PG, Plesner T. Monoclonal antibodies in myeloma. Clin Adv Hematol Oncol. 2015; 13(9):599-609. PMID: 26452191